Use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and lipid-lowering therapies among Rhode Islanders with diabetes enrolled in Medicare Part D plans in 2006 and 2007.
Kogut
Stephen
S
College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA. Kogut@URI.edu
Caffrey
Aisling
A
Pezzullo
Lynn
L
D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D014487:Centers for Medicare and Medicaid Services, U.S.; D003430:Cross-Sectional Studies; D016208:Databases, Factual; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D054524:Medicare Part D / Q000706:statistics & numerical data*; D008875:Middle Aged; D010342:Patient Acceptance of Health Care; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D011787:Quality of Health Care; D012237:Rhode Island; D014481:United States; D016903:Drug Monitoring
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents